Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Main features of the principal available multi-gene assays in breast cancer

From: Molecular characterization and targeted therapeutic approaches in breast cancer

Assay MammaPrint Oncotype DX PAM50
Number of genes 70 21 50 + 5 control genes
Sample Tissue core of fresh specimens preserved in RNA later or fresh-frozen tissue Formalin-fixed, paraffin- embedded tissue, or fresh-frozen tissue Formalin-fixed, paraffin- embedded tissue, or fresh-frozen tissue
Technique DNA microarray Quantitative PCR Quantitative PCR and nCounter technology
Study population Patients <61 years, with T1-T2, N0 disease (largely ER-positive) Patients with ER-positive, node-negative disease Patients with stage I to III breast cancer
Output Low- or high-risk patients Recurrence score: low, intermediate, or high Risk of recurrence: low, medium, or high
Guidelines FDA-approved National Comprehensive Cancer Network, American Society of Clinical Oncology FDA-cleared
Clinical applications Accurate and reproducible representation of BC biological features [7]. Overall risk assessment of BC recurrence [8]. BluePrint and MammaPrint improve stratification of patients in the neoadjuvant setting [14,16]. Accurate and reproducible representation of BC biological features [7]. Overall risk assessment of BC recurrence [8]. Prognostic role in tamoxifen-treated patients with positive nodes [13]. Prediction of CMF efficacy in ER-positive, node-negative BC patients [13]. Prediction of FAC efficacy in ER-positive, node-positive BC patients [7]. Accurate and reproducible representation of BC biological features [7]. Categorization of tumors into the four intrinsic subtypes [8,9]. Prediction of DFS and OS [9]. Estimate of the risk of relapse at 5 to 15 years in ER-positive, node-positive and -negative BC [10]. Prediction of benefit of tamoxifen in pre-menopausal patients [9].
  1. BC, breast cancer; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; DFS, disease-free survival; ER, estrogen receptor; FAC, fluorouracil, doxorubicin, and cyclophosphamide; FDA, US Food and Drug Administration; OS, overall survival; PAM50, Prediction Analysis of Microarray; PCR, polymerase chain reaction.